Cancer News
Breast cancer risk reduced by staying active and fit
New research shows: Postmenopausal women may have 20% less risk of breast cancer if they exercise vigorously. Women with the most body fat had 55% higher risk.
Reducing hair loss from chemotherapy: a new partnership
Researchers in partnership with the industry are analyzing the science required to stop hair loss from chemotherapy and improve cancer patients' quality of life.
Ovarian cancer risk could be lowered by tea and citrus products
Research has revealed that tea and citrus fruits and juices are associated with a reduced risk of ovarian cancer, after studying women aged 25-55 for 30 years.
Immunotherapy lung cancer drug shows promising results in trial
As part of a clinical trial, treatment of a common form of advanced lung cancer with an experimental immunotherapy drug led to promising 1-year survival rate.
Chest radiation for Wilms tumor increases breast cancer risk
A study shows that when a child receives chest radiation for Wilms tumor (a rare childhood cancer), it faces an increased risk of breast cancer later in life.
Prostate cancer: high cholesterol, triglycerides may raise recurrence risk
According to a new study, survivors of prostate cancer with higher levels of total cholesterol and triglycerides had an increased risk for disease recurrence.
Lung cancer can stay hidden for over 20 years, researchers say
According to a study, lung cancers can stay hidden for over 20 years before suddenly "turning on" and revealing themselves as an aggressive form of the disease.
Drug for 2 forms of leukemia & lymphoma approved in Europe
A new drug against adult relapsed or refractory mantle cell lymphoma (MCL), and adult chronic lymphocytic leukemia (CLL) has been approved in Europe.
Breast cancer risk predicted more efficiently by genomic sequencing
A new study shows that genomic sequencing can help women identify and manage their genetic risk for breast cancer better than what previously estimated.
Drug for BRCA mutated ovarian cancer one step closer to Europe
Olaparib, a drug for the maintenance treatment of platinum sensitive relapsed BRCA-mutated ovarian cancer has received positive opinion from European regulators.
More breast cancer patients choose reconstruction after mastectomy
New data from more than 1 million women shows that more high-risk breast cancer patients are choosing breast reconstruction after mastectomy.
Medication for nausea and vomiting from chemotherapy approved by US FDA
The US FDA has approved a drug (netupitant and palonosetron) for patients who experience nausea and vomiting while in chemotherapy.
Personalized therapy achieved complete remission in 90% of leukemia patients
Personalized treatment achieved remission in 90% of children & adults with acute lymphoblastic leukemia who relapsed or failed to respond to standard treatment.
New ovarian cancer test can help diagnosis and treatment selection
A new test may better diagnose ovarian cancer. The test will also help distinguish between benign and malignant tumors, and identify the type of malignant ones.
A targeted treatment could stop endometrial tumors from growing
A drug which targets a key gene mutation could stop an aggressive endometrial (or uterine or womb) cancer and shrink tumors, according to the latest research.
Experimental lung cancer drug designated as "breakthrough therapy"
An experimental drug against non-small cell lung cancer with a specific gene (ALK) mutation has been granted "breakthrough therapy" status by the US FDA.
Medication reduces nausea and vomiting caused by cisplatin chemotherapy
An agent called rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase 3 trial.
Some head and neck cancer patients benefit from afatinib
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck had improved outcomes from afatinib, compared to methotrexate, in a trial.
Fecal screening for colorectal cancer increases polyp detection by 89%
The introduction of a program for colorectal cancer screening every 2 years in a region in France increased the rate of diagnosis of high-risk polyps by 89%.
Patients with genetic mutation in lung cancer benefit in trial
72% of patients with a mutation-specific form of non-small cell lung cancer had an objective response, with median response duration approaching 1.5 years.
Remarkable benefit for HER2-positive metastatic breast cancer patients
HER2-positive metastatic breast cancer patients can benefit from the addition of an agent to standard treatment, in unprecedented results from a clinical trial.
Chemotherapy against pancreatic cancer more effective with vitamin D
A synthetic derivative of vitamin D may improve drugs' effectiveness against this very challenging cancer, by collapsing the cells around the tumor.
Some cervical cancer patients benefit from experimental drug in trial
Cervical cancer that has spread elsewhere, or has recurred after treatment, shrunk more when doctors added an experimental drug to standard chemotherapy.
New drug helps lung cancer patients with appetite and body mass
A new drug, anamorelin, helps advanced non-small cell lung cancer patients with their appetite and body mass, if they suffer from cancer anorexia and cachexia.
International studies: chemotherapy and radiotherapy safe for babies
Children exposed to chemotherapy/radiotherapy while in the womb suffer no negative mental or heart-related development impacts, based on international studies.
HER2-positive non-small cell lung cancer responds with targeted drugs
Patients who have non-small cell lung cancer with HER2 mutations may have options for treatment from targeted drugs.
Targeted treatment for some non-small cell lung cancers "effective"
Patients with a mutated subtype of non-small cell lung cancer benefited from a drug in a phase 2 trial presented in the latest oncology conference.
Patients whose melanoma has progressed may benefit from antibody
A monoclonal antibody called nivolumab shows response signs with superior rate and longer duration compared to standard chemotherapy in advanced melanoma.
Metastatic melanoma patients benefit from targeted combination therapy
A world-first study shows that a targeted combination drug treatment can reduce the risk of disease progression and death in patients with advanced melanoma.
Exercise can help chemotherapy shrink tumors
New research conducted in labs suggests that exercise may boost the effectiveness of chemotherapy in shrinking tumors.